Literature DB >> 28878604

The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer.

Tomoyuki Tatenuma1, Takashi Kawahara2, Yasuhide Miyoshi2, Kiyoshi Fujinami3, Junichi Ohta4, Kazuki Kobayashi5, Takeshi Kishida1, Masahiro Yao6, Hiroji Uemura2.   

Abstract

Entities:  

Year:  2017        PMID： 28878604      PMCID： PMC5582433          DOI： 10.1159/000447175

Source DB:  PubMed          Journal:  Curr Urol        ISSN： 1661-7649


× No keyword cloud information.
  5 in total

1.  Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.

Authors:  Fumimasa Fukuta; Hiroshi Kitamura; Masahiro Yanase; Keisuke Taguchi; Atsushi Takahashi; Yasuharu Kunishima; Masafumi Miyake; Hideki Adachi; Naoki Itoh; Takaoki Hirose; Seiji Takagi; Noriomi Miyao; Masanori Matsukawa; Masanori Shigyo; Naoya Masumori
Journal:  Jpn J Clin Oncol       Date:  2015-04-10       Impact factor: 3.019

2.  Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.

Authors:  Yasutomo Nakai; Kazuo Nishimura; Masashi Nakayama; Motohide Uemura; Hitoshi Takayama; Norio Nonomura; Akira Tsujimura
Journal:  Int J Clin Oncol       Date:  2013-03-01       Impact factor: 3.402

3.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

5.  Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.

Authors:  Takashi Kawahara; Yasuhide Miyoshi; Zenkichi Sekiguchi; Futoshi Sano; Narihiko Hayashi; Jun-ichi Teranishi; Hiroshi Misaki; Kazumi Noguchi; Yoshinobu Kubota; Hiroji Uemura
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.